Today: 28 December 2025
Subscribe

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50
20 December 2025
······
Uber Stock (NYSE: UBER) News on Dec. 20, 2025: Uber One Lawsuit, Robotaxi Momentum, and Analyst Forecasts Heading Into 2026

Uber Stock (NYSE: UBER) News on Dec. 20, 2025: Uber One Lawsuit, Robotaxi Momentum, and Analyst Forecasts Heading Into 2026

Uber Technologies, Inc. (NYSE: UBER) is ending 2025 with a split-screen narrative investors can’t ignore: strong operational momentum and expanding autonomous-vehicle partnerships on one side, and a fresh wave of regulatory/legal pressure tied to Uber One subscriptions on the other.
20 December 2025
·····
American Express (AXP) Stock News, Forecasts and Analysis for Dec. 20, 2025: Dividend Update, Holiday-Spend Momentum, and What Investors Are Watching Next

American Express (AXP) Stock News, Forecasts and Analysis for Dec. 20, 2025: Dividend Update, Holiday-Spend Momentum, and What Investors Are Watching Next

Dec. 20, 2025 — American Express Company (NYSE: AXP) is ending the year near fresh highs as investors weigh two competing narratives: a resilient premium-spending backdrop that continues to support card volumes and fee growth, and a late-2025 policy and
20 December 2025
····
Philip Morris International (PM) Stock News Today: Dividend, FDA Catalysts, and Wall Street Forecasts as of Dec. 20, 2025

Philip Morris International (PM) Stock News Today: Dividend, FDA Catalysts, and Wall Street Forecasts as of Dec. 20, 2025

Updated: December 20, 2025 — Philip Morris International Inc. (NYSE: PM) stock is ending the week in the spotlight as investors balance a resilient dividend story with a fast-moving U.S. “smoke-free” growth narrative built around ZYN nicotine pouches and the
20 December 2025
·····
Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Gilead Sciences Stock (NASDAQ: GILD) Today: TrumpRx Drug-Pricing Deal, HIV Pipeline Momentum, and Wall Street Forecasts (Dec. 20, 2025)

Updated: December 20, 2025 Gilead Sciences, Inc. (NASDAQ: GILD) heads into the weekend with fresh policy headlines, a high-profile pricing agreement tied to the Trump administration’s TrumpRx initiative, and renewed attention on the company’s next-generation HIV portfolio. The combination has
20 December 2025
·····
Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Intuit (INTU) Stock News, Forecasts and Analyst Outlook: USDC Stablecoin Deal, TurboTax 2026 Tax Push, and Key Catalysts (Dec. 20, 2025)

Dec. 20, 2025 — Intuit Inc. (NASDAQ: INTU) enters the weekend with investors balancing a fresh fintech headline—Intuit’s newly announced USDC stablecoin partnership with Circle—against the familiar seasonal catalyst that often defines the stock’s narrative: TurboTax demand heading into the
20 December 2025
·····
Adobe Stock (ADBE) News on Dec. 20, 2025: Earnings, AI Firefly Expansion, Runway & ChatGPT Deals, Analyst Price Targets, and Lawsuit Risk

Adobe Stock (ADBE) News on Dec. 20, 2025: Earnings, AI Firefly Expansion, Runway & ChatGPT Deals, Analyst Price Targets, and Lawsuit Risk

Adobe Inc. (NASDAQ: ADBE) heads into the final full week before year-end with a familiar split-screen story for investors: record results and upbeat fiscal 2026 targets on one side, and growing debate over AI-era competition and legal risk on the
20 December 2025
·····
1 … 208 209 210 211 212 … 1,554
Go toTop